Literature DB >> 23958752

Polyethylene glycol as an alternative polymer solvent for nanoparticle preparation.

Mohamed Ehab Ali1, Alf Lamprecht.   

Abstract

Solvent toxicity is one of the major drawbacks in the preparation of polymeric nanoparticles today. Here, polyethylene glycols (PEGs) are proposed as non-toxic solvents for the preparation of polymeric nanoparticles. Based on a preparation process similar to the solvent displacement technique, several process parameters were examined for their effects on the properties of the prepared nanoparticles by this method to achieve the optimum preparation conditions. The investigated parameters included polymer type and concentration, volume and temperature of the dispersing phase, methods of dispersing the solvent phase into the non-solvent phase, duration and speed of stirring and washing by dialysis. Ammonio methacrylate copolymer (Eudragit RL), poly-lactide-co-glycolide (PLGA), and PEG-PLGA were found to be successful polymer candidates for the preparation of nanoparticles by this method. Nanoparticles with diameters ranging from 80 to 400 nm can be obtained. The encapsulation efficiencies of bovine serum albumin, and lysozyme as model proteins were ranging from 7.3±2.2% to 69.3±1.8% depending on the strength of polymer-protein interaction. Biological assays confirmed a full lysozyme activity after the preparation process. PEG proved to be a suitable non-toxic solvent for the preparation of polymeric protein-loaded nanoparticles, maintaining the integrity of protein.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Eudragit; Non-toxic solvent; PLGA; Polyethylene glycol; Solvent displacement

Mesh:

Substances:

Year:  2013        PMID: 23958752     DOI: 10.1016/j.ijpharm.2013.07.077

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  6 in total

1.  Bridging laboratory and large scale production: preparation and in vitro-evaluation of photosensitizer-loaded nanocarrier devices for targeted drug delivery.

Authors:  Susanne Beyer; Li Xie; Susanna Gräfe; Vitali Vogel; Kerstin Dietrich; Arno Wiehe; Volker Albrecht; Werner Mäntele; Matthias G Wacker
Journal:  Pharm Res       Date:  2014-11-19       Impact factor: 4.200

2.  Effect of the excipient concentration on the pharmacokinetics of PM181104, a novel antimicrobial thiazolyl cyclic peptide antibiotic, following intravenous administration to mice.

Authors:  Vijayaphanikumar Yemparala; Anagha A Damre; Venkat Manohar; Kishori Sharan Singh; Girish B Mahajan; Satish N Sawant; Tanaji Deokule; H Sivaramakrishnan
Journal:  Results Pharma Sci       Date:  2014-09-10

3.  Drug delivery of 6-bromoindirubin-3'-glycerol-oxime ether employing poly(D,L-lactide-co-glycolide)-based nanoencapsulation techniques with sustainable solvents.

Authors:  Anna Czapka; Christian Grune; Patrick Schädel; Vivien Bachmann; Karl Scheuer; Michael Dirauf; Christine Weber; Alexios-Leandros Skaltsounis; Klaus D Jandt; Ulrich S Schubert; Dagmar Fischer; Oliver Werz
Journal:  J Nanobiotechnology       Date:  2022-01-04       Impact factor: 10.435

4.  Predicting Drug Release Rate of Implantable Matrices and Better Understanding of the Underlying Mechanisms through Experimental Design and Artificial Neural Network-Based Modelling.

Authors:  Ernő Benkő; Ilija German Ilič; Katalin Kristó; Géza Regdon; Ildikó Csóka; Klára Pintye-Hódi; Stane Srčič; Tamás Sovány
Journal:  Pharmaceutics       Date:  2022-01-19       Impact factor: 6.321

5.  The synergic antitumor effects of paclitaxel and temozolomide co-loaded in mPEG-PLGA nanoparticles on glioblastoma cells.

Authors:  Yuanyuan Xu; Ming Shen; Yiming Li; Ying Sun; Yanwei Teng; Yi Wang; Yourong Duan
Journal:  Oncotarget       Date:  2016-04-12

6.  A nanoparticle-based approach to improve the outcome of cancer active immunotherapy with lipopolysaccharides.

Authors:  Maryam A Shetab Boushehri; Mona M A Abdel-Mottaleb; Arnaud Béduneau; Yann Pellequer; Alf Lamprecht
Journal:  Drug Deliv       Date:  2018-11       Impact factor: 6.419

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.